Chris J van Koppen
Overview
Explore the profile of Chris J van Koppen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salah M, Tahoun M, Rudzitis-Auth J, Stotz L, van Koppen C, Laschke M, et al.
J Med Chem
. 2023 Jun;
66(13):8975-8992.
PMID: 37369108
Treating estrogen-dependent diseases like endometriosis with drugs suppressing local estrogen activation may be superior to existing endocrine therapies. Steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) are key enzymes...
2.
Gargano E, Mohamed A, Abdelsamie A, Mangiatordi G, Drzewiecka H, Jagodzinski P, et al.
ACS Med Chem Lett
. 2021 Dec;
12(12):1920-1924.
PMID: 34917255
In the face of the clinical challenge posed by non-small cell lung cancer (NSCLC), the present need for new therapeutic approaches is genuine. Up to now, no proof existed that...
3.
Hoogendoorn S, van Puijvelde G, van der Marel G, van Koppen C, Marco Timmers C, Overkleeft H
RSC Chem Biol
. 2021 Aug;
1(4):263-272.
PMID: 34458765
Fluorescent cell surface receptor agonists allow visualization of processes that are set in motion by receptor activation. This study describes the synthesis of two fluorescent, low molecular weight ligands for...
4.
Beck K, Telisman L, van Koppen C, Thompson 3rd G, Odermatt A
J Steroid Biochem Mol Biol
. 2020 Jan;
199:105605.
PMID: 31982514
Recent reports described cases of severe hypertension and hypokalemia accompanied by low renin and aldosterone levels during antifungal therapy with posaconazole and itraconazole. These conditions represent characteristics of secondary endocrine...
5.
Patt M, Beck K, Marco T, Jager M, Gonzalez-Ruiz V, Boccard J, et al.
Biochem Pharmacol
. 2019 Dec;
172:113781.
PMID: 31884045
Anabolic-androgenic steroids (AAS) are testosterone derivatives developed for steroid-replacement and treatment of debilitating conditions. They are widely used by athletes in elite sports and bodybuilding due to their muscle-building and...
6.
Abdelsamie A, Salah M, Siebenburger L, Merabet A, Scheuer C, Frotscher M, et al.
J Med Chem
. 2019 Jul;
62(15):7289-7301.
PMID: 31343176
Osteoporosis is predominantly treated with drugs that inhibit further bone resorption due to estrogen deficiency. Yet, osteoporosis drugs that not only inhibit bone resorption but also stimulate bone formation, such...
7.
Muller S, Pahlig S, Merabet A, Abdelsamie A, van Koppen C, Marchais-Oberwinkler S, et al.
J Steroid Biochem Mol Biol
. 2019 Jun;
192:105405.
PMID: 31185280
Hormone replacement therapy is a viable option to protect bone from postmenopausal osteoporosis. Systemically elevated estrogen levels, however, are disadvantageous because of the risk of harmful side effects in other...
8.
Abdelsamie A, Salah M, Siebenburger L, Hamed M, Borger C, van Koppen C, et al.
Eur J Med Chem
. 2019 Jun;
178:93-107.
PMID: 31176098
Estrogens are the major female sex steroid hormones, estradiol (E2) being the most potent form in humans. Disturbing the balance between E2 and its weakly active oxidized form estrone (E1)...
9.
Abdelsamie A, Herath S, Biskupek Y, Borger C, Siebenburger L, Salah M, et al.
J Med Chem
. 2019 Jan;
62(3):1362-1372.
PMID: 30645111
Current therapies of steroid hormone-dependent diseases predominantly alter steroid hormone concentrations (or their actions) in plasma, in target and nontarget tissues alike, rather than in target organs only. Targeted therapy...
10.
Siebenbuerger L, Hernandez-Olmos V, Abdelsamie A, Frotscher M, van Koppen C, Marchais-Oberwinkler S, et al.
J Med Chem
. 2018 Nov;
61(23):10724-10738.
PMID: 30480443
Intracellular elevation of E2 levels in bone by inhibition of 17β hydroxysteroid dehydrogenase type 2 (17β-HSD2) without affecting systemic E2 levels is an attractive approach for a targeted therapy against...